scholarly journals The significance of a new parameter – plasma protein binding – in therapeutic drug monitoring and its application to carbamazepine in epileptic patients

RSC Advances ◽  
2017 ◽  
Vol 7 (45) ◽  
pp. 28048-28055 ◽  
Author(s):  
Jing-lin Gao ◽  
Xin-yu Wang ◽  
Jing An ◽  
Chao-hui Du ◽  
Meng-jiao Li ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Protein Binding ◽  
Plasma Protein Binding ◽  
Plasma Protein ◽  
Drug Monitoring ◽  
Drug Dosage ◽  
Therapeutic Drug ◽  
Dosage Regimens ◽  
Epileptic Patients

The primary cause of the variability of Cf in pharmacology is the change in plasma protein binding (PPB), thus PPB monitoring should be applied to a better individualization of drug dosage regimens in clinical patients.

Immunosuppressant quantification in intravenous microdialysate – towards novel quasi-continuous therapeutic drug monitoring in transplanted patients

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Susanne Weber ◽  
Sara Tombelli ◽  
Ambra Giannetti ◽  
Cosimo Trono ◽  
Mark O’Connell ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Real Time ◽  
Drug Monitoring ◽  
Time Course ◽  
Drug Dosage ◽  
Immunosuppressive Drug ◽  
Therapeutic Drug ◽  
Continuous Sampling ◽  
Real Time Analysis ◽  
Drug Concentrations

AbstractObjectivesTherapeutic drug monitoring (TDM) plays a crucial role in personalized medicine. It helps clinicians to tailor drug dosage for optimized therapy through understanding the underlying complex pharmacokinetics and pharmacodynamics. Conventional, non-continuous TDM fails to provide real-time information, which is particularly important for the initial phase of immunosuppressant therapy, e.g., with cyclosporine (CsA) and mycophenolic acid (MPA).MethodsWe analyzed the time course over 8 h of total and free of immunosuppressive drug (CsA and MPA) concentrations measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in 16 kidney transplant patients. Besides repeated blood sampling, intravenous microdialysis was used for continuous sampling. Free drug concentrations were determined from ultracentrifuged EDTA-plasma (UC) and compared with the drug concentrations in the respective microdialysate (µD). µDs were additionally analyzed for free CsA using a novel immunosensor chip integrated into a fluorescence detection platform. The potential of microdialysis coupled with an optical immunosensor for the TDM of immunosuppressants was assessed.ResultsUsing LC-MS/MS, the free concentrations of CsA (fCsA) and MPA (fMPA) were detectable and the time courses of total and free CsA comparable. fCsA and fMPA and area-under-the-curves (AUCs) in µDs correlated well with those determined in UCs (r≥0.79 and r≥0.88, respectively). Moreover, fCsA in µDs measured with the immunosensor correlated clearly with those determined by LC-MS/MS (r=0.82).ConclusionsThe new microdialysis-supported immunosensor allows real-time analysis of immunosuppressants and tailor-made dosing according to the AUC concept. It readily lends itself to future applications as minimally invasive and continuous near-patient TDM.

scholarly journals The Variability of Plasma Protein Binding of Phenytoin in Epileptic Patients with Hypoalbuminemia

1985 ◽  
Vol 105 (5) ◽  
pp. 475-480
Author(s):  
KUMIKO MAMADA ◽  
YASUJI KASUYA ◽  
JIN HENMI ◽  
YOICHI TAKAHASHI ◽  
KAZUHIRO SOMEYA ◽  
...  
Keyword(s):  
Protein Binding ◽  
Plasma Protein Binding ◽  
Plasma Protein ◽  
Epileptic Patients

Therapeutic Drug Monitoring of Suramin and Protein Binding

1991 ◽  
Vol 14 (20) ◽  
pp. 3719-3733 ◽  
Author(s):  
Ernst A. De Bruijn ◽  
Greet Pattyn ◽  
Louis Denis ◽  
Charles Mahler ◽  
Allan T. Van Oosterom ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Protein Binding ◽  
Drug Monitoring ◽  
Therapeutic Drug

scholarly journals An Aptamer-Based Biosensor for the Azole Class of Antifungal Drugs

mSphere ◽  
2017 ◽  
Vol 2 (4) ◽  
Author(s):  
Gregory R. Wiedman ◽  
Yanan Zhao ◽  
Arkady Mustaev ◽  
Jinglei Ping ◽  
Ramya Vishnubhotla ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Field Effect ◽  
Field Effect Transistor ◽  
Drug Dosage ◽  
Antifungal Drugs ◽  
Therapeutic Drug ◽  
Drug Concentrations ◽  
Graphene Field Effect Transistor ◽  
Effect Transistor

ABSTRACT We have developed the first aptamer directed toward the azole class of antifungal drugs and a functional biosensor for these drugs. This aptamer has a unique secondary structure that allows it to bind to highly hydrophobic drugs. The aptamer works as a capture component of a graphene field effect transistor device. These devices can provide a quick and easy assay for determining drug concentrations. These will be useful for therapeutic drug monitoring of azole antifungal drugs, which is necessary to deal with the complex drug dosage profiles. This technical report describes the development of an aptamer for sensing azole antifungal drugs during therapeutic drug monitoring. Modified synthetic evolution of ligands through exponential enrichment (SELEX) was used to discover a DNA aptamer recognizing azole class antifungal drugs. This aptamer undergoes a secondary structural change upon binding to its target molecule, as shown through fluorescence anisotropy-based binding measurements. Experiments using circular dichroism spectroscopy revealed a unique G-quadruplex structure that was essential and specific for binding to the azole antifungal target. Aptamer-functionalized graphene field effect transistor (GFET) devices were created and used to measure the strength of binding of azole antifungals to this surface. In total, this aptamer and the supporting sensing platform provide a valuable tool for therapeutic drug monitoring of patients with invasive fungal infections. IMPORTANCE We have developed the first aptamer directed toward the azole class of antifungal drugs and a functional biosensor for these drugs. This aptamer has a unique secondary structure that allows it to bind to highly hydrophobic drugs. The aptamer works as a capture component of a graphene field effect transistor device. These devices can provide a quick and easy assay for determining drug concentrations. These will be useful for therapeutic drug monitoring of azole antifungal drugs, which is necessary to deal with the complex drug dosage profiles.

Aminoglycoside Dosage Regimens After Therapeutic Drug Monitoring

2002 ◽  
Vol 41 (10) ◽  
pp. 791-792 ◽  
Author(s):  
Carl M.J. Kirkpatrick ◽  
Evan J. Begg ◽  
Murray L. Barclay ◽  
Stephen B. Duffull
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Dosage Regimens
Sign in / Sign up

Export Citation Format

Share Document